We investigated whether TCRs restricted to the more ubiquitously expressed MHC class I molecules could be used to re-direct human Tregs. By utilizing a series of HLA-A2 restricted TCRs that recognize the same peptide-MHC class I complex (pMHC) with affinities varying up to a 3500-fold difference, we observed that TCR affinity had no effect on the ability of the introduced TCRs to confer potent antigen-specific suppressive activity. Surprisingly, we found a naturally occurring, low affinity MHC class I restricted TCR specific for an NY-ESO-1 epitope that was unable to re-direct a functional CD4 T effector response could confer potent antigen-specific suppressive activity when expressed in Tregs and severely impair the expansion of highly functional HIV-1 GAG specific CD8 T cells expressing a high affinity TCR. Importantly, this suppressive activity was only observed when both antigens were presented by the same cell and no suppression was observed when the target antigens were put in distinct cells.
. This approach would provide a way to rapidly generate therapeutic levels of antigen-specific Tregs 6 , which in many murine-based studies have proven to be far superior to polyclonal Tregs in preventing, as well as treating, autoimmune diseases such as type 1 diabetes, multiple sclerosis, and arthritis 7 . Moreover, many of the tissues targeted by autoimmune cells tend to lack the ability to express MHC class II. Thus, endogenous, as well as exogenously introduced MHC class II restricted TCRs specific for an autoimmune antigen expressed in Tregs, may fail to accumulate and become activated near the target tissue, potentially hindering the overall therapeutic effectiveness of Treg-based therapies. One way to overcome these limitations is to engineer Tregs to express MHC class I restricted TCRs, provided they retain full suppressive activity in the absence of CD8.
For personal use only. on October 31, 2017 . by guest www.bloodjournal.org From Previously, it was shown that tumor-specific, MHC class I restricted TCRs that were engineered to be high affinity variants could bypass the need for CD8 expression and confer function to CD4 T cells, suggesting that only high affinity MHC class I restricted TCRs are functional in CD4 + Tregs 8 . Use of high affinity
TCRs may be further advantageous as several studies have shown that
augmented TCR affinity has correlated with improved Teff function [8] [9] [10] [11] [12] , though in many cases there was a maximal improvement in T cell function that could not be improved by further augmentation of TCR affinity. Moreover, several TCRs with exceptionally high affinity for pMHC have lost specificity, cautioning that excessive enhancement of TCR affinity may be detrimental 8, 11 . Together, these data suggest that for each TCR and for each therapeutic application there is an optimal TCR affinity 13, 14 . Here, we probed how TCR affinity affects Treg function in an effort to determine how to best deploy MHC class I restricted TCRs for use in adoptive Treg therapy. Our studies show that in contrast with Teffs and contrary to our predictions and previous studies 15 , augmented TCR affinity does not affect/improve Treg function. Furthermore, these studies suggest that Tregs expressing non-engineered, MHC class I restricted TCRs will be fully functional and therapeutically attractive as long as the Treg and Teff target the same cell as we failed to detect bystander suppression when the target antigen of the effector and Treg was expressed in distinct cells.
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An identical amount of HLA A2-NY-ESO-1 was immobilized onto one flow cell as a negative control as previously described 10 .
Generation of aAPC. K562-based aAPC lines were generated as previously described 20 . The dsRED SL9 lentiviral construct was generated by fusing dsRED to HIV-1 GAG 54-102 and cloning this into pELPS 24 and the entire NY-ESO, codon- In vitro suppression assay. The CFSE-based suppression assay was performed as previously described 26 . The bead-based assay was performed by mixing washed, expanded Tregs with various ratios of TCR transduced Teff.
Treg-Teff mixtures were stimulated with aAPCs, and 5 days later the absolute number of CD8 T cells was determined by flow cytometry using CountBright absolute counting beads (Invitrogen) added to the FASC tubes in addition to anti-CD8 mAb, and SL9 tetramer. Data were acquired on a LSR II flow cytometer using the FACSDiva software. Percent suppression was calculated using the formula: 1 -# effector T cell divisions in suppressed condition/# effector T cell divisions in unsuppressed condition x 100.
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Results
Generation of MHC class I specific TCRs with varying affinity for the same pMHC. In order to determine whether MHC class I restricted TCRs could be used to effectively re-target human Tregs, we employed a previously described HIV-1 GAG specific TCR that recognized the peptide SLYNTVATL (SL9) in the context of HLA-A2. This particular TCR was attractive for these studies because a high affinity variant (a11/b6) was previously generated 10 Moreover, because the wildtype A2-SL9 awt/bwt TCR has the highest affinity of any naturally occurring human TCR described to date 10 , we wished to obtain a TCR that had a lower affinity more representative of natural TCRs. To this end, we identified a TCR pair (a2/b1) that had a TCR affinity ~5 fold less than the awt/bwt. After characterizing the relative affinity of each A2-SL9-specific TCR, we converted these soluble TCRs into full length TCRs and inserted them into both lentiviral and RNA expression vectors 10 . As the awt/b6 and a11/bwt A2-SL9-specific TCRs had similar affinities, we chose to study only the awt/b6 TCR. , we first wanted to test whether A2-SL9 specific TCRs could also function in CD4 T cells. We generated RNA encoding each A2-SL9-specific TCR and transfected this RNA into freshly isolated CD4 T cells. One day post-transfection, TCR expression was evaluated by tetramer staining, and all A2-SL9 TCR transfected T cell cultures could bind A2-SL9 specific tetramer in a CD8 independent manner (Fig. 1A) . Next, we asked whether these TCRs could re-direct a functional CD4
T cell effector response. To do this, we co-cultured A2-SL9 specific TCRtransfected CD4 T cells with K562-based artificial APCs (aAPCs) 30 that expressed HLA-A2, the full length NY-ESO-1 gene connected to GFP via an IRES sequence, and a minigene that encoded the 50 amino acids that surround the SL9 epitope in the HIV-1 GAG gene (Fig. 1B) Nonetheless, the overall level of Treg transduction was robust and should not limit the ability of using TCR-transduced Tregs for antigen-specific adoptive T cell therapy. Next, we determined whether TCR transduction altered the ability of the Tregs to suppress in a non-antigen-specific manner. We evaluated the ability of awt/b6 A2-SL9 TCR-transduced Tregs to function in a conventional Treg suppression assay in which expanded transduced or untransduced Tregs were mixed with CFSE labeled PBMCs at various ratios along with anti-CD3 mAb coated beads. In agreement with our previous studies 18, 19 , expanded Tregs isolated from cord blood were highly suppressive regardless of whether they had been TCR transduced or not, maintaining greater than 90% suppression activity at a 8:1 Teff:Treg ratio in the experiment shown ( Fig 2B) and greater than 75% activity in all three replicate experiments (Fig 2C) . The average suppression of polyclonal Tregs was 84% ± 11.7, and that of awt/b6 A2-SL9 TCR transduced
Tregs was 82 ± 8.4 at 8:1 Teff: Treg ratio. This difference was not significant (p=.751). Thus, TCR transduction does not alter the ability of Tregs to function in a non-antigen-specific suppressive assay. . Importantly, TCR transduced Tregs maintain an anergic state as they were unable produce IL-2 upon PMA + ionomycin stimulation (Fig. 3D) .
MHC class I restricted TCR transduced
Since cord blood by definition is limited as source material of Tregs, multiple rounds of expansion may be required to obtain therapeutic numbers. Our data show that even though Tregs are less susceptible to lentiviral transduction, use of antigen-expressing aAPCs would be an effective way to further expand highly functional Tregs while simultaneously enriching for a TCR-transduced population.
These data also indicate that MHC class I restricted TCRs can convey the necessary signals to promote the activation and expansion of CD4+ human
Tregs.
Tregs transduced with MHC class I restricted TCR can suppress in an
antigen-specific manner. Next, we asked whether TCR transduced Tregs could suppress in an antigen-specific manner. Since ex vivo expanded, antigenspecific Tregs would likely be used to treat an ongoing autoimmune disease, we wished to determine whether antigen-specific Tregs could efficiently suppress previously primed Teffs. To this end, we isolated cord blood Tregs, and either transduced them with awt/b6 A2-SL9 TCR or left them untransduced, then expanded these populations for 13-18 days. The expanded Tregs were then mixed at various ratios with expanded adult CD8 T cell effectors that had been
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From transduced with the awt/b6 A2-SL9 TCR and co-cultured with K.64.A2.SL9.4-1BBL aAPCs. In preliminary studies, we found that expanded Teffs did not uniformly label with CFSE, which limited our ability to accurately measure cell division. Therefore, we developed a bead-based system that allowed us to quantitatively count the absolute number of A2-SL9-specific CD8 T cells present in the culture 5 days after restimulation. In pilot studies using freshly isolated Teff, we obtained similar data using CFSE and bead methods for measuring Treg suppressive activity (Supplemental Fig. 1 ), indicating that these two assays for measuring suppressive activity are equivalent. We observed that highly rested, untransduced Tregs had limited ability to block antigen-specific CD8 T cell expansion. In contrast, similarly highly rested Tregs that expressed an A2-SL9-specific TCR were able to potently suppress A2-SL9-specific T cell expansion when present at a minimum ratio of 1:8 Treg to Teff ratio (Fig. 4A) . We repeated this experiment with four cord blood samples and compiled the degree of A2-SL9-specific Teff suppression induced by the Tregs at a 1:4 (Treg:Teff) ratio.
The TCR engineered Tregs suppressed 57 ± 10% of the cell divisions observed, whereas the non-TCR transduced Tregs could only suppress 15% ± 11% of the cell divisions observed (Fig. 4B, p=0 .001). These data indicate that MHC class I restricted TCRs can promote antigen-specific suppression when introduced into human Tregs.
Previously, we demonstrated that primary human CD8 T cells transduced with a high affinity A2-SL9-specific TCR (a11/b6) displayed augmented effector functions, were able to control HIV-1 replication at low effector to target ratios, and could respond to cognate antigen in a highly polyfunctional manner 10 . We were interested in determining whether high affinity TCRs could confer improved suppressive activity to TCR transduced antigen-specific Tregs. We thus transduced the panel of A2-SL9-specific TCRs into freshly isolated cord blood Tregs and expanded these cells for 13-18 days until they stopped expanding and resumed a near resting cell volume as previously described 19 . To determine whether expanded, antigen-specific Tregs could also prevent the initial activation of potentially autoimmune T cells, we generated antigen-specific Teff by electroporating RNA encoding the lowest (a2/b1) or high affinity (a11/b6) A2-SL9-specific TCR into freshly isolated, CFSE labeled primary human CD8 T cells. A2-SL9 antigen-specific Tregs and Teff were mixed in all pairwise combinations using various Treg to Teff ratios, and the CD8 T cell proliferation in response K.A2.SL9.NY-ESO-1 aAPCs was assessed by CFSE dilution (Fig. 4C) .
In contrast to what we observed in Teffs 10 , TCR affinity did not modulate Treg suppressive activity. Tregs expressing the lowest affinity TCRs were equally potent in blocking antigen-specific Teff expansion as those bearing the high affinity TCRs. These data also indicate that TCR transduced Tregs are equally adept at blocking ongoing as well as newly initiated Teff responses.
A MHC class I restricted TCR that is unable to redirect CD4 T effector responses is capable of conferring robust antigen-specific suppression to
Tregs. For most autoimmune diseases, the epitope(s) targeted by the immune system are unknown, and at present it is not logistically feasible to identify autoimmune target(s) and then develop a custom, antigen-specific therapy for each patient. Thus, it would be desirable to develop Tregs that can become activated within a target tissue and suppress autoimmune cells of the same and of distinct specificities. To determine whether MHC class I restricted TCRtransduced Tregs could mediate dominant tolerance 35 , we employed the previously described HLA-A2 restricted NY-ESO-1 157-164 SLLMWITQC (A2-SC9) wildtype TCR, which has an affinity between 13-32μM 8 . Unlike what we observed with the A2-SL9-specific TCRs (Fig. 1A) , A2-SC9 tetramer could not bind the CD4 T cells transfected (a 50:50 mixture of CD4 and CD8 T cells was transfected) with the A2-SC9 TCR despite high expression of the introduced Vβ chain (Figs. 5A-D) . This indicates that even though A2-SC9 TCR is well expressed in the CD4 T cells, there is only a limited ability of the A2-SC9 tetramer to bind to A2-SC9 TCR expressing cells. For comparison, we performed a similar analysis with the lowest affinity A2-SL9 specific TCR (a2/b1).
As expected, we found that both SL9-specific tetramer and the anti-Vβ5 antibodies could recognize the TCR at similar frequencies (Figs. 5E-H) . Next, using the K.A2.SL9.NY-ESO-1 aAPCs (Fig. 1B) we asked whether A2-SC9 TCRs could redirect a CD4 Teff response. Consistent with previous reports 11, 13 , we were unable to detect an antigen-specific, CD4 T cell response to the NY-ESO-1 antigen. Importantly, as mentioned above, in this experiment, an equal number of CD8 T cells were mixed with the CD4 T cells, and we observed an NY-ESO-1 specific cytokine response in CD8 T cells, thereby demonstrating that the A2-SC9 effector responses are CD8 dependent (Fig. 5I) .
Next, we tested whether Tregs expressing the A2-SC9 TCR were functional. We generated awt/b6 A2-SL9 specific effector CD8 T cells by RNA transfection and labeled them with CFSE. We mixed these Teffs with either polyclonal (Fig. 5J) , A2-SL9-specific (Fig. 5K) , or A2-SC9-specific (Fig. 5L) Tregs at various ratios and determined the ability K.A2.SL9.NYESO-1 aAPCs to drive the expansion of the high affinity A2-SL9 specific Teffs. The TCR transfected Tregs bound the respective specific tetramer and Vβ Ab similar to the CD4 T effector cells shown in Fig 5A-H (data not shown) . While the polyclonal Tregs could suppress when mixed at a 4:1 Teff:Treg ratio, this suppressive activity was not observed at ratios of 8:1 and below (Fig. 5J) . In contrast, Tregs expressing the same high affinity awt/b6 A2-SL9 TCR as the Teff were able to suppress Teff expansion even when diluted to a 32:1 Teff:Treg ratio (Fig. 5K) . Interestingly, Tregs expressing the A2-SC9 TCR, which was unable to redirect a CD4 Teff response (Fig. 5I) , showed much higher suppressive activity than polyclonal Tregs and as much activity as A2-SL9 specific Tregs (Fig. 5L) . These results indicate that non-engineered MHC class I restricted TCRs can suppress highly potent CD8 T cells that recognize a distinct pMHC complex being co-presented on the same target tissue as the Treg target antigen.
Target antigens must be expressed on the same cell to observe immunosuppression. We next investigated whether the target antigens of both the effectors and Tregs needed to be presented by the same aAPC to observe (Fig 6A,B) . In contrast, as described in Fig 5, when the A2-SL9 expressing CD8 effectors were mixed with A2-SC9 Tregs and aAPCs that expressed both antigens (K.A2.SL9.NY-ESO-1), we observed potent, antigenspecific suppression of the A2-SL9 response by the A2-SC9 Tregs (Fig 6C,D) .
These data indicate that both the effector and Tregs must be activated by the same aAPC to observe bystander suppression.
For
Discussion
A striking finding of our study is that a low affinity, MHC class I restricted TCR that was unable to provide antigen-specific Teff activity in the absence of CD8 was able to redirect the suppressive activity of Tregs as well as a high affinity TCR that could confer Teff function to CD4 T cells. One interpretation of these data is that Tregs are less dependent on strong TCR signaling than Teff. There are a number of reports that indicate weaker TCR signals drive the differentiation of Teff to Tregs [35] [36] [37] [38] [39] ; however, the precise relationship between TCR affinity, the number of TCRs triggered, duration of these signaling events, and the ability to generate functional Tregs is complicated, as a recent study showed that low amounts of a strong TCR agonist gave rise to Tregs that persisted the longest in vivo 40 . Our studies demonstrate that while increased TCR affinity did not improve suppressive activity as we previously observed for CD8 T cell responses, increased affinity also did not impair suppressive activity. 42 , though a more recent paper using a knock-in rather than a transgenic model could not completely replicate this finding 43 . In any case, our studies examined the ability of mature The results from the first in-human trial that used expanded Tregs to prevent GVHD demonstrate that isolating, expanding, and infusing adoptively transferred Tregs is both feasible and safe, and furthermore, there are hints that this type of therapy will be efficacious 46 . The next series of challenges for the Treg cellular therapy field is to determine what kind and how many of a particular type of Treg should be used to effectively treat a particular disease state. For instance, the rationale to use polyclonal Tregs to prevent or treat acute GVHD is strong 47 .
Here, the Tregs can be administered prior to disease initiation, at the time of transplant, and since the exact target antigens are unknown in GVHD, the broad specificity of polyclonal Tregs is attractive. Autoimmune diseases such as type 1 diabetes and multiple sclerosis may present different challenges to Treg cellular therapy. Here, the autoimmune disease is generally well established before Treg therapy can be initiated. Moreover, these diseases are confined to a specific tissue, so therapies that can target this particular tissue are more likely to have therapeutic benefits and less likely to cause global immunosuppression. There are many ways to generate antigen-specific Tregs to treat autoimmune disease. These T cell mixtures were stimulated with the aAPCs described in Fig 1B, These Tregs were mixed at various ratios with CFSE-labeled CD8 T cells that had been transfected with awt/b6 A2-SL9 specific TCR. These T cell mixtures were stimulated with aAPC described in Fig. 1B , and CFSE dilution was measured 5 days later by flow cytometry. % suppression was calculated as described in the Methods. 
